Sialoglycans and Siglecs Can Shape the Tumor Immune Microenvironment

Publikation: Bidrag til tidsskrift › Tidsskriftartikel › Forskning › fagfællebedømt

Standard

Sialoglycans and Siglecs Can Shape the Tumor Immune Microenvironment. / van de Wall, Stephanie; Santegoets, Kim; van Houtum, Eline; Büll, Christian; Adema, Gosse.

I: Trends in Immunology, Bind 41, Nr. 4, 2020, s. 274-285.

Publikation: Bidrag til tidsskrift › Tidsskriftartikel › Forskning › fagfællebedømt

Harvard

van de Wall, S, Santegoets, K, van Houtum, E, Büll, C & Adema, G 2020, 'Sialoglycans and Siglecs Can Shape the Tumor Immune Microenvironment', Trends in Immunology, bind 41, nr. 4, s. 274-285. https://doi.org/10.1016/j.it.2020.02.001

APA

van de Wall, S., Santegoets, K., van Houtum, E., Büll, C., & Adema, G. (2020). Sialoglycans and Siglecs Can Shape the Tumor Immune Microenvironment. Trends in Immunology, 41(4), 274-285. https://doi.org/10.1016/j.it.2020.02.001

Vancouver

van de Wall S, Santegoets K, van Houtum E, Büll C, Adema G. Sialoglycans and Siglecs Can Shape the Tumor Immune Microenvironment. Trends in Immunology. 2020;41(4):274-285. https://doi.org/10.1016/j.it.2020.02.001

Author

van de Wall, Stephanie ; Santegoets, Kim ; van Houtum, Eline ; Büll, Christian ; Adema, Gosse. / Sialoglycans and Siglecs Can Shape the Tumor Immune Microenvironment. I: Trends in Immunology. 2020 ; Bind 41, Nr. 4. s. 274-285.

Bibtex

@article{9a564016074343ecadc884df0b0103af,
title = "Sialoglycans and Siglecs Can Shape the Tumor Immune Microenvironment",
abstract = "Sialic acid sugar-carrying glycans, sialoglycans, are aberrantly expressed on many tumor cells and have emerged as potent regulatory molecules involved in creating a tumor-supportive microenvironment. Sialoglycans can be recognized by sialic acid-binding immunoglobulin-like lectins (Siglecs), a family of immunomodulatory receptors. Most mammalian Siglecs transmit inhibitory signals comparable with the immune checkpoint inhibitor programmed death protein 1 (PD-1), but some are activating. Recent studies have shown that tumor cells can exploit sialoglycan–Siglec interactions to modulate immune cell function, contributing to an immunosuppressive tumor microenvironment (TME). Interference with sialoglycan synthesis or sialoglycan–Siglec interactions might improve antitumor immunity. Many questions regarding specificity, signaling, and regulatory function of sialoglycan–Siglec interactions remain. We posit that sialoglycans and Siglecs present as potential glyco-immune {\textquoteleft}checkpoints{\textquoteright} for cancer immunotherapy.",
author = "{van de Wall}, Stephanie and Kim Santegoets and {van Houtum}, Eline and Christian B{\"u}ll and Gosse Adema",
year = "2020",
doi = "10.1016/j.it.2020.02.001",
language = "English",
volume = "41",
pages = "274--285",
journal = "Trends in Immunology",
issn = "1471-4906",
publisher = "Elsevier Ltd. * Trends Journals",
number = "4",

}

RIS

TY - JOUR

T1 - Sialoglycans and Siglecs Can Shape the Tumor Immune Microenvironment

AU - van de Wall, Stephanie

AU - Santegoets, Kim

AU - van Houtum, Eline

AU - Büll, Christian

AU - Adema, Gosse

PY - 2020

Y1 - 2020

N2 - Sialic acid sugar-carrying glycans, sialoglycans, are aberrantly expressed on many tumor cells and have emerged as potent regulatory molecules involved in creating a tumor-supportive microenvironment. Sialoglycans can be recognized by sialic acid-binding immunoglobulin-like lectins (Siglecs), a family of immunomodulatory receptors. Most mammalian Siglecs transmit inhibitory signals comparable with the immune checkpoint inhibitor programmed death protein 1 (PD-1), but some are activating. Recent studies have shown that tumor cells can exploit sialoglycan–Siglec interactions to modulate immune cell function, contributing to an immunosuppressive tumor microenvironment (TME). Interference with sialoglycan synthesis or sialoglycan–Siglec interactions might improve antitumor immunity. Many questions regarding specificity, signaling, and regulatory function of sialoglycan–Siglec interactions remain. We posit that sialoglycans and Siglecs present as potential glyco-immune ‘checkpoints’ for cancer immunotherapy.

AB - Sialic acid sugar-carrying glycans, sialoglycans, are aberrantly expressed on many tumor cells and have emerged as potent regulatory molecules involved in creating a tumor-supportive microenvironment. Sialoglycans can be recognized by sialic acid-binding immunoglobulin-like lectins (Siglecs), a family of immunomodulatory receptors. Most mammalian Siglecs transmit inhibitory signals comparable with the immune checkpoint inhibitor programmed death protein 1 (PD-1), but some are activating. Recent studies have shown that tumor cells can exploit sialoglycan–Siglec interactions to modulate immune cell function, contributing to an immunosuppressive tumor microenvironment (TME). Interference with sialoglycan synthesis or sialoglycan–Siglec interactions might improve antitumor immunity. Many questions regarding specificity, signaling, and regulatory function of sialoglycan–Siglec interactions remain. We posit that sialoglycans and Siglecs present as potential glyco-immune ‘checkpoints’ for cancer immunotherapy.

U2 - 10.1016/j.it.2020.02.001

DO - 10.1016/j.it.2020.02.001

M3 - Journal article

C2 - 32139317

VL - 41

SP - 274

EP - 285

JO - Trends in Immunology

JF - Trends in Immunology

SN - 1471-4906

IS - 4

ER -

ID: 237092634